158 related articles for article (PubMed ID: 35001412)
1. Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel HM
Br J Clin Pharmacol; 2022 Jun; 88(6):2899-2908. PubMed ID: 35001412
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
6. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies.
Yin W; Facius A; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2024 Mar; 17(3):e13722. PubMed ID: 38445548
[TBL] [Abstract][Full Text] [Related]
8. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor.
Nishi T; Metcalf CS; Fujimoto S; Hasegawa S; Miyamoto M; Sunahara E; Watanabe S; Kondo S; White HS
Epilepsia; 2022 Jun; 63(6):1580-1590. PubMed ID: 35316533
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE).
Demarest S; Jeste S; Agarwal N; Arkilo D; Asgharnejad M; Hsiao S; Thibert R
Epilepsy Behav; 2023 May; 142():109173. PubMed ID: 37011526
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
Ismat FA; Usansky HH; Villa R; Zou J; Teper A
Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.
Yin W; Ballard TE; Zhu SX; Hsiao S; Chen H; Li Y; Chowdhury SK; Stevenson A; Hui T; Hunt A; Asgharnejad M; Han S
Br J Clin Pharmacol; 2024 Feb; 90(2):516-527. PubMed ID: 37771051
[TBL] [Abstract][Full Text] [Related]
12. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults.
Yin W; Facius A; Wagner T; Tsai M; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2023 Jul; 16(7):1149-1162. PubMed ID: 37212649
[TBL] [Abstract][Full Text] [Related]
16. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.
Nishi T; Kondo S; Miyamoto M; Watanabe S; Hasegawa S; Kondo S; Yano J; Watanabe E; Ishi T; Yoshikawa M; Ando HK; Farnaby W; Fujimoto S; Sunahara E; Ohori M; During MJ; Kuroita T; Koike T
Sci Rep; 2020 Oct; 10(1):17081. PubMed ID: 33051477
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of [
Koike T; Constantinescu CC; Ikeda S; Nishi T; Sunahara E; Miyamoto M; Cole P; Barret O; Alagille D; Papin C; Morley T; Fowles K; Seibyl J; Tamagnan G; Kuroita T
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1148-1156. PubMed ID: 34651220
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
Macha S; Brand T; Meinicke T; Link J; Broedl UC
Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
